Repligen | RGEN - Market Capitalization


Repligen reported $9.7B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Agilent USD 39.08B 6.43B Jun/2026
Align Technology USD 10.33B 1.75B Sep/2026
BioMarin Pharmaceutical USD 11.15B 91M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Bruker USD 9.16B 3.66B Jun/2026
Charles River Laboratories USD 10.39B 2.54B Jun/2026
Danaher USD 157.81B 18.96B Sep/2026
Dentsply International USD 2.13B 191M Jun/2026
General Electric Aerospace USD 324.02B 65.91B Sep/2026
Henry Schein USD 9.68B 1.4B Jun/2026
Illumina USD 37.12B 3.64B Nov/2026
IQVIA Holdings USD 48.06B 3.81B Nov/2026
Mettler Toledo International USD 25.82B 278M Jun/2026
OraSure Technologies USD 174M 61M Dec/2025
Pacific Biosciences Of California USD 565M 180M Dec/2025
Pfizer USD 138.44B 15.37B Jun/2026
Repligen USD 9.74B 1.1B Nov/2026
Revvity USD 12.69B 2.75B Jun/2026
Standard Biotools USD 227M 95M Nov/2026
Thermo Fisher Scientific USD 249.58B 58.93B Sep/2026
Waters USD 37.24B 7.38B Jun/2026
West Pharmaceutical Services USD 26.09B 730M Sep/2026